ATE366809T1 - Addressine der schleimhaut und der blutgefässe und ihre verwendung - Google Patents

Addressine der schleimhaut und der blutgefässe und ihre verwendung

Info

Publication number
ATE366809T1
ATE366809T1 AT96906504T AT96906504T ATE366809T1 AT E366809 T1 ATE366809 T1 AT E366809T1 AT 96906504 T AT96906504 T AT 96906504T AT 96906504 T AT96906504 T AT 96906504T AT E366809 T1 ATE366809 T1 AT E366809T1
Authority
AT
Austria
Prior art keywords
madcam
primate
recombinant
proteins
relates
Prior art date
Application number
AT96906504T
Other languages
English (en)
Inventor
Michael J Briskin
Douglas J Ringler
Dominic Picarella
Walter Newman
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27011628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366809(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/386,857 external-priority patent/US6551593B1/en
Priority claimed from US08/523,004 external-priority patent/US7750137B2/en
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE366809T1 publication Critical patent/ATE366809T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
AT96906504T 1995-02-10 1996-02-12 Addressine der schleimhaut und der blutgefässe und ihre verwendung ATE366809T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/386,857 US6551593B1 (en) 1995-02-10 1995-02-10 Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US08/523,004 US7750137B2 (en) 1995-09-01 1995-09-01 Mucosal vascular addressins

Publications (1)

Publication Number Publication Date
ATE366809T1 true ATE366809T1 (de) 2007-08-15

Family

ID=27011628

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96906504T ATE366809T1 (de) 1995-02-10 1996-02-12 Addressine der schleimhaut und der blutgefässe und ihre verwendung

Country Status (12)

Country Link
EP (1) EP0808367B1 (de)
JP (1) JP4205162B2 (de)
AT (1) ATE366809T1 (de)
AU (1) AU4986296A (de)
CA (1) CA2212702C (de)
DE (1) DE69637155T2 (de)
DK (1) DK0808367T3 (de)
ES (1) ES2290955T3 (de)
MX (1) MX9706049A (de)
NZ (1) NZ303523A (de)
PT (1) PT808367E (de)
WO (1) WO1996024673A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503271A (ja) * 1996-11-01 2001-03-13 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド ヒト粘膜アドレシン細胞接着分子―1(MAdCAM―1)およびそのスプライス変異体
WO1998051345A2 (en) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Method for dislodging infiltrated leukocytes from a tissue
JP4817494B2 (ja) * 1998-05-13 2011-11-16 ジェネンテック, インコーポレイテッド 肝疾患の診断及び治療
AU2007201698B2 (en) * 1998-05-13 2011-10-13 Genentech, Inc. Diagnosis and treatment of hepatic disorders
US7090845B2 (en) 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
AUPR524101A0 (en) * 2001-05-25 2001-06-21 Council Of The Queensland Institute Of Medical Research, The Antigen targeting
AU2002351194A1 (en) * 2001-11-30 2003-06-17 Incyte Genomics, Inc. Cell adhesion and extracellular matrix proteins
US20070202097A1 (en) * 2003-03-10 2007-08-30 Krissansen Geoffrey W Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
BRPI0409850A (pt) 2003-05-01 2006-05-09 Scripps Research Inst antagonistas seletivos de r-caderina e métodos
DOP2005000002A (es) * 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
PE20070374A1 (es) * 2005-07-08 2007-05-12 Pfizer Ltd ANTICUERPOS ANTI-MAdCAM
WO2007007152A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
WO2009140684A2 (en) * 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
UY34054A (es) 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP3224280A1 (de) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab zur behandlung von fistelbildendem morbus crohn
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. 抗α4β7インテグリン抗体による治療の結果の予測
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
EP3430052A2 (de) 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Verfahren zur vorbeugung der transplantat-wirt-krankheit
MA43755A (fr) 2016-03-14 2018-11-28 Millennium Pharm Inc Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
JP7162533B2 (ja) 2016-05-04 2022-10-28 ミレニアム ファーマシューティカルズ, インコーポレイテッド 炎症性腸疾患の治療を目的とする三剤併用療法
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
IL270201B2 (en) 2017-04-28 2026-05-01 Millennium Pharm Inc A method for treating childhood disorders
KR102787394B1 (ko) 2017-07-14 2025-03-26 화이자 인크. MAdCAM에 대한 항체
AU2020279240A1 (en) * 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
EP4720125A1 (de) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7-integrin-antikörperzusammensetzungen und verfahren zur verwendung
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
EP4762093A1 (de) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha-4-beta-7-integrinbindende proteine und verfahren zur verwendung
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5675794A (en) * 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression

Also Published As

Publication number Publication date
DE69637155D1 (de) 2007-08-23
CA2212702C (en) 2010-04-20
EP0808367B1 (de) 2007-07-11
PT808367E (pt) 2007-10-22
DE69637155T2 (de) 2008-02-07
WO1996024673A1 (en) 1996-08-15
JPH10513365A (ja) 1998-12-22
AU4986296A (en) 1996-08-27
MX9706049A (es) 1998-02-28
JP4205162B2 (ja) 2009-01-07
NZ303523A (en) 2002-02-01
ES2290955T3 (es) 2008-02-16
DK0808367T3 (da) 2007-11-05
CA2212702A1 (en) 1996-08-15
EP0808367A1 (de) 1997-11-26

Similar Documents

Publication Publication Date Title
DE69637155D1 (de) Addressine der schleimhaut und der blutgefässe und ihre verwendung
Geiser et al. The interleukin-8-related chemotactic cytokines GRO alpha, GRO beta, and GRO gamma activate human neutrophil and basophil leukocytes
ES2063350T5 (es) Nuevas proteinas con efecto inhibidor del tnf y su obtencion.
Wuyts et al. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties
CA2073045C (en) A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
KR101151805B1 (ko) 바이포달 펩타이드 바인더
US20060173162A1 (en) Bactericidak anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp)
JP2742925B2 (ja) 血栓形成抑制用治療薬組成物
Okamoto et al. Total chemical synthesis and biological activities of glycosylated and non‐glycosylated forms of the chemokines CCL1 and Ser‐CCL1
Kokot et al. Tamm-Horsfall protein updated
WO1996022371A3 (en) C-C CHEMOKINE RECEPTOR 3: CKP-3 OR Eos-L2
KR970002917B1 (ko) 인터루킨-i 억제제
JPH03204896A (ja) インターフェロンレセプター細胞外断片
EP0616615B1 (de) Analoge des menschlichen Interleukin-8.
CN101553243A (zh) 组织损伤修复中的基质细胞衍生因子1的蛋白酶抗性突变体
KR100237936B1 (ko) 인터루킨-1 길항제
Campistol et al. Polymerization of normal and intact β2-microglobulin as the amyloidogenic protein in dialysis-amyloidosis
DK0486572T3 (da) Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
EP1683866B1 (de) Deletionsmutanten des IgE-abhängigen Histamin-Releasing-Faktor (HRF) mit der Fähigkeit zur Histaminfreisetzung, HRF-bindende Peptide sowie deren Verwendung
CN111848780A (zh) 一种IL-36的可溶性受体sIL-36R及其应用
EP0698666B1 (de) Modifiziertes Epimorphin
Deyl et al. Collagen αA and αB chains constitute two separate molecular species
EP0612349B1 (de) Neues thrombininhibitorisches protein aus raubwanzen
CA2310677C (en) In vitro and in vivo growth-promoting proteins and peptides for kidney epithelial cells
JP2000109500A (ja) ヒト尿由来細胞接着糖蛋白質、その製造方法およびそれを 含有する医薬品